An initial single intravenous immunoglobulin therapy drugs for Kawasaki disease

  Toshimasa Nakada Summary of this Paper: An initial single intravenous immunoglobulin therapy with delayed administration of anti- ...

 

Toshimasa Nakada

Summary of this Paper: An initial single intravenous immunoglobulin therapy with delayed administration of anti- inflammatory drugs for Kawasaki disease

GJMR: Global Journals Blog

                                   Toshimasa Nakada

                                   Department of Pediatrics, Aomori Prefectural Central Hospital

Biography

Toshimasa Nakada graduated from the Hirosaki University School of Medicine in 1981 and acquired MD in 1988. I have given medical care and have studied as a pediatrician at Aomori Prefectural Central Hospital from 1988. I am also clinical assistant professor of Hirosaki University of Medicine.

I interested in the interaction between intravenous immunoglobulin ( IVIG ) therapy and anti-inflammatory drugs ( aspirin / flurbiprofen ) in the acute phase treatment of Kawasaki disease in 2003. The study by Ito H and Kiyosawa N inspired me to research on this topic [1]. I began the trial about an initial single IVIG therapy with delayed administration of anti- inflammatory drugs in the acute phase treatment of this disease from 2004.

I found the difference in the prevalence of coronary artery lesions ( CAL ) in Kawasaki disease according to the time of initiation of additional aspirin or flurbiprofen therapy on 2012 [2]. Using logistic regression analysis, another study, which included patients who received IVIG therapy with and without delayed administration of anti-inflammatory drugs, showed that the significant variable for CAL development was the delayed administration of anti-inflammatory drugs and 2 g/kg/day IVIG therapy and that the type of anti-inflammatory drugs was not significant [3]. Furthermore, recent studies disclosed that variable factors including IVIG resistance, responsiveness, and relapse of disease were associated with CAL complications and that an initial single IVIG therapy might be useful for the prevention of large CAL caused by different factors of Kawasaki disease [4,5].

I had an opportunity of expert presentation about these findings at 4th International Conference and Exhibition on Immunology ( September 28-30, 2015 Houston, Texas, USA ). I submitted this presentation to Global Journal [6]. The process to publish was smooth. One of the most important points for future works in this field is to establish the additional therapies after an initial single IVIG therapy.

References

1. Ito H, Kiyosawa N. Effectiveness of aspirin therapy in acute phase of Kawasaki disease. Prog Med 2002; 22:1640–1643
2. Nakada T. Difference in the prevalence of coronary arterial lesions in Kawasaki disease according to the time of initiation of additional aspirin or flurbiprofen therapy. Med J Aomori 2012; 57:15–19
3. Nakada T. Effects of anti-inflammatory drugs on intravenous immunoglobulin therapy in the acute phase of Kawasaki disease. Pediatr Cardiol 2015; 36: 335-339
4. Nakada T. Prevention of large coronary artery lesions caused by Kawasaki disease. Medical Research Archives 2015 DOI:http://dx.doi.org/10.18103/mra.v0i3.138
5. Nakada T. Background factors associated with the complications of coronary artery lesions caused by Kawasaki disease. Clinical Medicine Research 2015; 4: 127-131 (http://www.sciencepublishinggroup.com/j/cmr)
6. Nakada T: Usefulness of an initial single intravenous immunoglobulin therapy for Kawasaki disease. Global Journal of Medical Research: F Diseases 2015; 15:15-17

Research article:
https://globaljournals.org/GJMR_Volume15/3-Usefulness-of-an-Initial-Single.pdf
Published by Global Journals



                                                     © Global Journals Official Blog